CGG CGG

Viridien: Information on the total number of voting rights and shares

Viridien: Information on the total number of voting rights and shares

Viridien

A French société anonyme

with a share capital of € 7,161,465

Registered office: 27 avenue Carnot, 91300 Massy, France

Evry Trade and Companies Register 969 202 241

Information on the total number of voting rights and shares

Pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial markets authority

(AMF- Autorité des Marchés Financiers)

Date of the informationTotal number of issued sharesNumber of actual voting rights*Number of theoretical voting rights**
June 30, 2024716,146,563718,856,835718,881,831

* All of the Company shares have the same voting rights, except for treasury shares which do not have voting rights and registered shares held for more than two years, which have double voting rights.

** Pursuant to Article 223-11 of the General Regulation of the French Financial markets authority, the number of theoretical voting rights is calculated based on the shares having either single or double voting rights, including treasury shares which are deprived of voting rights.

Attachment



EN
01/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CGG

Baptiste Lebacq
  • Baptiste Lebacq

Viridien : Vers un momemtum moins soutenu du côté de SMO

>Opinion Surperformance et OC ajusté à 80 € - Post publication et contact société, nous ajustons en baisse nos attentes d’EBITDA 2024/26 de 6% en moyenne. L’activité SMO devrait continuer de pénaliser la formation des résultats du groupe d’où l’annonce de mesures d’ajustements structurelles par le groupe dans cette branche (réduction des capacités sur Houston, fermeture de Singapour et annonce d’une réduction de 150 postes en France). Nous réitérons notre recommandati...

Baptiste Lebacq
  • Baptiste Lebacq

Viridien : Towards less favourable momentum in SMO

>Outperform recommendation and target price adjusted to € 80 - Post-publication and company contact, we have adjusted down our EBITDA forecast for 2024-2026 by 6% on average. The SMO activity continued to penalise the formation of group’s results hence the announcement of structural adjustment measures at this activity (reduction of capacity in Houston, closure of Singapore and announcement of 150 jobs losses in France). We reiterate our Outperform recommendation and...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch